alpha-MSH comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
| Property | Value | Notes |
|---|---|---|
| Storage form | Lyophilized powder | Longer stability at -20 °C |
| Reconstitution solvent | Sterile water or buffer | Depends on intended application |
| Purity assessment | Reverse-phase HPLC | Reported as peak area percentage |
| Identity confirmation | Mass spectrometry | Compared against theoretical mass |
| Main stability concern | Repeated freeze-thaw | May promote aggregation |
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
==== Electrospinning ==== Electrospinning is a highly versatile technique that can be used to produce continuous fibers ranging in diameter from a few microns to a few nanometers. In a typical electrospinning set-up, the desired scaffold material is dissolved within a solvent and placed within a syringe. This solution is fed through a needle and a high voltage is applied to the tip and to a conductive collection surface. The buildup of electrostatic forces within the solution causes it to eject a thin fibrous stream towards the oppositely charged or grounded collection surface. During this process the solvent evaporates, leaving solid fibers leaving a highly porous network. This technique is highly tunable, with variation to solvent, voltage, working distance (distance from the needle to collection surface), flow rate of solution, solute concentration, and collection surface. This allows for precise control of fiber morphology. On a commercial level however, due to scalability reasons, there are 40 or sometimes 96 needles involved operating at once. The bottle-necks in such set-ups are: 1) Maintaining the aforementioned variables uniformly for all of the needles and 2) formation of "beads" in single fibers that we as engineers, want to be of a uniform diameter. By modifying variables such as the distance to collector, magnitude of applied voltage, or solution flow rate – researchers can dramatically change the overall scaffold architecture.
Transition options for transgender adolescents and youth are significantly limited compared to those for transgender adults. Prepubescent transgender youth can go through various social changes, such as presenting as their gender and asking to be called by a different name or different pronouns. Medical options for transition become available once the child begins to enter puberty. Under close supervision by a team of doctors, puberty blockers may be used to limit the effects of puberty. Discrimination has a significant effect on the mental health of young transgender people. The lack of family acceptance, rejection in schools and abuse from peers can be powerful stressors, leading to poor mental health and substance abuse. A study done on transgender youth in San Francisco found that higher rates of both transgender-based and racial bias are associated with increased rates of depression, post-traumatic stress disorder, and suicidal ideation. The Swiss National Advisory Commission on Biomedical Ethics (NCE) has suggested that research into treatments for gender-incongruent and gender-diverse young people should routinely consider the impact of social factors, including discrimination and social support, when analyzing their results. In a 2018 review, evidence suggested that hormonal treatments for transgender adolescents can achieve their intended physical effects.
Electroencephalography – may have a characteristic generalized periodic sharp wave pattern. Periodic sharp wave complexes develop in half of the people with sporadic CJD, particularly in the later stages. Cerebrospinal fluid (CSF) analysis for elevated levels of 14-3-3 protein and tau protein could be supportive in the diagnosis of sCJD. The two proteins are released into the CSF by damaged nerve cells. Increased levels of tau or 14-3-3 proteins are seen in 90% of prion diseases. The markers have a specificity of 95% in clinical symptoms suggestive of CJD, but specificity is 70% in other, less characteristic cases. 14-3-3 and tau proteins may also be elevated in the CSF after ischemic strokes, inflammatory brain diseases, or seizures. The protein markers are also less specific in early CJD, genetic CJD or the bovine variant. However, a positive result should not be regarded as sufficient for the diagnosis. The real-time quaking-induced conversion (RT-QuIC) assay, which amplifies misfolded PrPSc, now plays a central role in CJD diagnosis. Second-generation RT-QuIC on cerebrospinal fluid has sensitivity in the 90–97% range and ~100% specificity in sporadic CJD, far superior to earlier CSF tests. A positive RT-QuIC (on CSF or other tissues) is now included as a criterion for probable CJD in many national surveillance centers. Studies have shown RT-QuIC can also be done on olfactory mucosa swabs obtained via nasal brushing and on skin biopsies, with high diagnostic accuracy (reported sensitivities ~90–100%).
=== Cyclic peptides === Extensive research has been performed on nanotubes formed by stacking cyclic peptides with an even number of alternating D and L amino acids. These nanotubes are the narrowest formed by peptides. The stacking occurs through intermolecular hydrogen bonding, and the end product is a cylindrical structure with the amino acid side chains of the peptide defining the properties of the outer surface of the tube and the peptide backbone determining the properties of the inner surface of the tube. Polymers can also be covalently attached to the peptides, in which case a polymer shell around the nanotube can be formed. By applying peptide design, the inner diameter, which is completely uniform, can be specified; the outer surface properties can also be affected by peptide design. Therefore, these cyclic nanotubes can form in a range of different environments.
Sources: en.wikipedia.org
=== Medical use === The appeal of conotoxins for creating pharmaceutical drugs is the precision and speed with which the chemicals act; many of the compounds target only a particular class of receptor. This means that they can reliably and quickly produce a particular effect on the body's systems without side effects; for example, almost instantly reducing heart rate or turning off the signaling of a single class of nerve, such as pain receptors. Ziconotide, a powerful atypical painkiller, was initially isolated from the venom of the magician cone snail, Conus magus. It was approved by the U.S. Food and Drug Administration in December 2004 under the name Prialt. Other drugs based on cone snail venom targeting Alzheimer's disease, Parkinson's disease, depression, and epilepsy are in clinical or preclinical trials. Many peptides produced by the cone snails show prospects for being potent pharmaceuticals, such as AVC1, isolated from the Australian species, the Queen Victoria cone, Conus victoriae, and have been highly effective in treating postsurgical and neuropathic pain, even accelerating recovery from nerve injury. Geography and tulip cone snails, as well as the Conus kinoshitai, are known to secrete a type of insulin that paralyzes nearby fish by causing hypoglycaemic shock. They are the only two non-human animal species known to use insulin as a weapon. Cone snail insulin is capable of binding to human insulin receptors and researchers are studying its use as a potent fast-acting therapeutic insulin.
For example, the Archbishop of Reggio Calabria, Carmelo Pujia, an interventionist on the eve of World War, had a prayer composed praising the glory of the homeland and the Italian flag. Under the Fascist regime, concentration camps were built in Calabria and used to imprison foreigners whose presence was considered undesirable, such as Chinese immigrants and foreign (though not Italian) Jews together with members of the Romani minority, whose nomadic lifestyle was viewed as anti-social. The camps operated from 1938 to 1943. They were harsh, butt not death camps, (the majority of those imprisoned survived).
== Products and services == GoodRx started its telemedicine service GoodRx Care in September 2019. It lets people talk to a licensed provider online for common issues and get prescriptions even if they don't have insurance. They also run condition-specific subscription plans that bundle online doctor visits, FDA-approved meds, and home delivery into one monthly payment. On the weight management side, GoodRx offers prescriptions for GLP-1 drugs like semaglutide through their telemedicine platform. This got a boost when the oral version of Wegovy became widely available in the US in early 2026. GoodRx works with drug makers like Novo Nordisk to make some medications (including semaglutide options) more affordable for people paying cash. The telemedicine part took off after GoodRx bought HeyDoctor in 2019 and brought their virtual care tools into the main platform.
Sources: en.wikipedia.org
== Structure == Mammalian GPX1, GPX2, GPX3, and GPX4 (this protein) have been shown to be selenium-containing enzymes, whereas GPX6 is a selenoprotein in humans with cysteine-containing homologues in rodents. In selenoproteins, the amino acid selenocysteine is inserted in the nascent polypeptide chain during the process of translational recoding of the UGA stop codon. GPX4 shares the amino acid motif of selenocysteine, glutamine, and tryptophan (catalytic triad) with other glutathione peroxidases.
=== Mites and insects === Ivermectin is also used to treat infection with parasitic arthropods. Scabies – infestation with the mite Sarcoptes scabiei – is most commonly treated with topical permethrin or oral ivermectin. A single application of permethrin is more efficacious than a single treatment of ivermectin. For most scabies cases, ivermectin is used in a two-dose regimen: the first dose kills the active mites, but not their eggs. Over the next week, the eggs hatch, and a second dose kills the newly hatched mites. The two-dose regimen of ivermectin has similar efficacy to the single dose permethrin treatment. Ivermectin is, however, more effective than permethrin when used in the mass treatment of endemic scabies. Similarly, oral ivermectin is increasingly used to control scabies outbreaks in semi-closed institutions (care homes, refugee camps, prisons etc.), where mass topical treatments often fail for logistical reasons. For severe "crusted scabies", where the parasite burden is orders of magnitude higher than usual, the CDC recommends up to seven doses of ivermectin over the course of a month, along with a topical antiparasitic. Both head lice and pubic lice can be treated with oral ivermectin, an ivermectin lotion applied directly to the affected area, or various other insecticides. Ivermectin is also used to treat rosacea and blepharitis, both of which can be caused or exacerbated by Demodex folliculorum mites.
The FDA has identified that breast implants may be associated with a rare form of cancer called anaplastic large-cell lymphoma (ALCL), which some experts believe is believed to be associated with chronic bacterial inflammation. Similar ALCL phenomena have been seen with other types of medical implants including vascular access ports, orthopedic hip implants, and jaw (TMJ) implants. The causal association between breast implants and ALCL was conclusively established in December 2013, when researchers at MD Anderson Cancer Center published a study of 60 women with breast implants who were diagnosed with ALCL in the breast. In 2015, plastic surgeons published an article reviewing 37 articles in the literature on 79 patients and collected another 94 unreported cases, resulting in 173 women with breast implants who had developed ALCL of the breast. They concluded that "Breast implant-associated ALCL is a novel manifestation of site- and material-specific lymphoma originating in a specific scar location, presenting a wide array of diverse characteristics and suggesting a multifactorial cause." They stated that "There was no preference for saline or silicone fill or for cosmetic or reconstructive indications." Where implant history was known, the patient had received at least one textured-surface device. In 2016, the World Health Organization (WHO) officially recognized BIA-ALCL. As of April 2022, the FDA has received 1,130 global medical device reports (MDRs) of BIA-ALCL, including 59 deaths.
Sources: en.wikipedia.org
Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.
Reverse-phase HPLC separates components by hydrophobicity and reports purity as a percentage of total peak area. It does not by itself confirm molecular identity. Mass spectrometry is used alongside it for that purpose.
They link a specific lot to its analytical results and storage history. This traceability supports reproducibility when results differ between experiments. Records also help identify when re-testing is warranted.
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.